The oral medicine used for myelodysplastic syndromes (MDS) is the decitabine and cedazuridine combination.
Understanding the Oral Treatment for MDS
According to information updated January 31, 2024, the combination of decitabine and cedazuridine is an oral medication prescribed for treating myelodysplastic syndromes (MDS).
What is MDS?
Myelodysplastic syndromes (MDS) are a group of cancers affecting the bone marrow. In individuals with MDS, the immature blood cells produced in the bone marrow fail to develop properly into healthy, mature blood cells. This can lead to various health issues, including certain types of anemia.
Who is this Medicine For?
The decitabine and cedazuridine combination is indicated for:
- Myelodysplastic syndromes (MDS)
- Chronic myelomonocytic leukemia (CMML)
- Certain types of anemia associated with these conditions
This oral therapy provides an alternative administration route for a type of treatment traditionally given intravenously.
This information is based on the provided reference regarding the use of the decitabine and cedazuridine combination as an oral treatment option for these blood disorders.
